Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mCRPC Cohort | Adult male patients with a recent diagnosis of mCRPC in PRECISION. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients by Prior Therapies | Baseline | |
| Number of Patients by Number of Post-index Lines of Therapy (LOTs) | Up to approximately 5 years | |
| Number of Patients by Type of Therapy at Each LOT | Up to approximately 5 years | |
| Percentage of Patients Switching From One Type of Therapy to Another at Each LOT | Up to approximately 5 years | |
| Time to First-line (1L) Treatment Initiation (TTTI) | Time from index date (mCRPC diagnosis) to the start of 1L treatment. | Up to approximately 5 years |
| Time to Next Therapy (TTNT) for Each LOT | Time from the end of each LOT to initiation of the next LOT. | Up to approximately 5 years |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Patients by Patient Characteristics | Patient characteristics include race, geographical region, insurance status, marital status, type of treatment center, comorbidities, Gleason score, disease stage at diagnosis, and prostate-specific antigen (PSA) level. | Baseline |
| Age |
Not provided
Inclusion criteria:
Exclusion criteria:
• None
Not provided
Not provided
Adult male patients with a confirmed mCRPC diagnosis in the US in the last 5 years who are included in the PRECISION data platform.
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Novartis Pharmaceuticals | Contact | +41613241111 | novartis.email@novartis.com | |
| Novartis Pharmaceuticals | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Novartis Pharmaceuticals | Novartis Pharmaceuticals | Study Director |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline |
| Progression-free Survival (PFS) From Index Date | PFS from index date: time from mCRPC diagnosis (index date) until progression or death from any cause. | Up to approximately 5 years |
| PFS From Each LOT | PFS from each LOT, among those with that LOT: time from the date of initiation of the LOT until progression or death from any cause. | Up to approximately 5 years |
| Overall Survival (OS) From Index Date | OS from index date: time from mCRPC diagnosis (index date) until death from any cause. | Up to approximately 5 years |
| OS From Each LOT | OS from each LOT, among those with that LOT: time from the date of initiation of the LOT until death from any cause. | Up to approximately 5 years |
| ID | Term |
|---|---|
| D064129 | Prostatic Neoplasms, Castration-Resistant |
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
Not provided
Not provided